Baird Medical Accelerates Global Commercial Roadmap with Strategic Clinical Education Initiatives in the U.S. and Japan

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) anunció programas de educación clínica en EE. UU. y Japón para acelerar la adopción global de su tecnología de Ablación por Microondas (MWA) para tumores benignos de tiroides. La empresa lideró una capacitación avanzada en la Universidad de Columbia y un taller en la Showa Medical University para estandarizar las técnicas de tiroidología intervencional y ampliar las opciones para pacientes no quirúrgicos.

News Market Reaction

+9.73%

3 alerts

+9.73% News Effect

+3.1% Peak Tracked

+$3M Valuation Impact

$37M Market Cap

0.9x Rel. Volume

On the day this news was published, BDMD gained 9.73%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $37M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Warrant shares registered: 11,500,000 shares Resale shares registered: 34,415,562 shares Warrant exercise price: US$11.50 per share +5 more

8 metrics

Warrant shares registered 11,500,000 shares Ordinary shares issuable upon exercise of public warrants

Resale shares registered 34,415,562 shares Ordinary shares registered for resale by existing shareholders

Warrant exercise price US$11.50 per share Exercise price of public warrants

Share price reference US$1.63 Nasdaq share price on December 4, 2025 cited in filing

Resale share proportion 70.9% Resale shares as portion of shares outstanding after exercises/conversions

Current price US$0.9294 Pre-news trading level on latest close

52-week high US$7.2616 Pre-news 52-week high

52-week low US$0.901 Pre-news 52-week low

Market Reality Check

Price: $0.9550 Vol: Volume 63,897 is 0.44x th...

low vol

$0.9550 Last Close

Volume Volume 63,897 is 0.44x the 20-day average 144,056, indicating subdued trading interest pre-announcement. low

Technical Shares at 0.9294 are well below the 200-day MA of 2.64 and only slightly above the 52-week low of 0.901, far from the 52-week high of 7.2616.

Peers on Argus

BDMD was up 1.74% with no peers in the real-time momentum scanner. Broader medic...

BDMD was up 1.74% with no peers in the real-time momentum scanner. Broader medical-device peers showed mixed moves (e.g., ICAD and ICCM up, APYX and XTNT down), pointing to a stock-specific reaction rather than a coordinated sector move.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Clinical education event	Positive	+6.9%	Gynecology microwave ablation masterclass to train physicians across Asia.
Jan 26	Strategic partnership	Positive	+0.0%	Partnership to use Hainan Free Trade Port as hub for global commercialization.
Jan 20	Investor conference	Positive	-0.9%	JP Morgan Healthcare Conference meetings to discuss strategy and MWA adoption.
Jan 07	Regulatory approvals	Positive	+3.9%	Product registrations in Pakistan and Vietnam enabling new market entries.
Dec 17	Manufacturing expansion	Positive	+2.2%	Establishment of U.S. manufacturing base with MPS Medical for global supply.

Pattern Detected

Recent news around global expansion, manufacturing, and education has more often been followed by positive one-day price reactions than negative ones.

Recent Company History

Over the past few months, BDMD has repeatedly highlighted its global commercialization push. It established a U.S. manufacturing base on Dec. 17, 2025, secured regulatory approvals in Pakistan and Vietnam on Jan. 7, 2026, and engaged investors at the 2026 J.P. Morgan Healthcare Conference on Jan. 20. Subsequent news on partnerships and physician-education masterclasses reinforced this strategy. Today’s U.S. and Japan clinical education initiatives continue that theme of expanding minimally invasive MWA adoption and physician training across key markets.

Market Pulse Summary

The stock moved +9.7% in the session following this news. A strong positive reaction aligns with BDM...

Analysis

The stock moved +9.7% in the session following this news. A strong positive reaction aligns with BDMD’s pattern of favorable responses to global expansion and education news, where several recent announcements saw positive one-day moves. However, the stock traded near its 52-week low of 0.901 and well below its 200-day MA of 2.64, highlighting prior weakness. The sizable registered resale overhang of 34,415,562 shares and broader regulatory risks noted in filings could still weigh on longer-term sentiment.

Key Terms

microwave ablation, interventional thyroidology, benign thyroid tumors, public warrants, +1 more

5 terms

microwave ablation medical

"a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced"

Microwave ablation is a medical procedure that uses focused microwave energy to heat and destroy abnormal tissue, such as tumors, through a needle-like probe inserted into the body; think of it as using a tiny, targeted microwave oven to cook away problem cells without large incisions. It matters to investors because it represents a growing category of minimally invasive treatments that can reduce hospital stays, create demand for specialized devices and disposables, and influence reimbursement and adoption trends in healthcare markets.

interventional thyroidology medical

"accelerate its global expansion by establishing standardized clinical excellence for interventional thyroidology."

Interventional thyroidology is the medical field that treats thyroid problems using minimally invasive procedures—such as image-guided needle therapies, thermal or chemical ablation, and targeted drainages—instead of open surgery. For investors, it matters because these procedures drive demand for specialized devices, training, and outpatient services, can lower costs and recovery time for patients, and influence reimbursement and market growth for companies supplying the equipment and clinics.

benign thyroid tumors medical

"Microwave Ablation System for the treatment of Benign Thyroid Tumors."

Benign thyroid tumors are noncancerous lumps in the thyroid gland, the small hormone-making organ in the neck; they do not invade nearby tissue or spread to other organs. They matter to investors because how often they occur, how they are detected, and how they are treated affects demand for diagnostic tools, drugs and procedures—similar to a common, manageable household repair that creates predictable ongoing business for companies in healthcare and biotech.

public warrants financial

"ordinary shares issuable upon exercise of public warrants at US$11.50 per share"

Public warrants are tradable securities that give the holder the right to buy a company’s stock at a fixed price before a set expiration date. Like a coupon that lets you purchase shares later at a preset price, they matter to investors because using them can bring new cash into the company but also increase the total number of shares outstanding, which can dilute existing ownership and influence the stock’s price and potential gains.

hfCAA regulatory

"warns that HFCAA-related auditor inspection issues could eventually lead to a Nasdaq delisting"

The HFCAA is a U.S. law that requires companies listed on U.S. stock exchanges to allow their auditors to be inspected by U.S. regulators; if a company’s auditors can’t be reviewed for several years, the company risks being removed from U.S. markets. For investors, it matters because the law increases transparency and audit oversight—think of it as a safety inspection for a car—while also creating a clear regulatory trigger that can affect a stock’s availability and price if compliance can’t be shown.

AI-generated analysis. Not financial advice.

NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the execution of premier clinical education programs in the United States and Japan. These strategic engagements reinforce Baird Medical's market leadership and accelerate its global expansion by establishing standardized clinical excellence for interventional thyroidology.

In New York, the Company successfully facilitated an advanced training initiative at the Columbia University Irving Medical Center, led by Dr. Jennifer Kuo, Director of the Interventional Endocrinology Program and Fellowship Director at Columbia University. This high-level collaboration empowered distinguished specialists Dr. Todd Frieze and Dr. Alberto Monreal from Duke Health, to refine techniques in minimally invasive therapies, including Baird Medical´s Microwave Ablation System for the treatment of Benign Thyroid Tumors. By leveraging Dr. Kuo's expertise, Baird Medical empowers top-tier institutions to adopt and standardize advanced ablation procedures, expanding patient access to non-surgical options.

Simultaneously, Baird Medical solidified its presence in Asia through a high-profile workshop at Showa Medical University in Yokohama. Opening with remarks from Professor Nobuhiro Fukunari and featuring insights from Professor Ming-An Yu of the China-Japan Friendship Hospital, the event fostered critical academic exchange. This initiative underscores the Company's commitment to driving the adoption of thyroid ablation across international markets through peer-to-peer education.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-accelerates-global-commercial-roadmap-with-strategic-clinical-education-initiatives-in-the-us-and-japan-302682296.html

SOURCE BDMD

FAQ

What clinical education did Baird Medical (BDMD) run at Columbia University on Feb 9, 2026?

Baird Medical conducted an advanced training initiative at Columbia University led by Dr. Jennifer Kuo. According to the company, the program trained specialists from top centers to refine minimally invasive Microwave Ablation techniques for benign thyroid tumors.

How does the BDMD workshop in Yokohama support Baird Medical's Asia expansion?

The Yokohama workshop at Showa Medical University fostered academic exchange with regional experts. According to the company, the event aimed to drive adoption of thyroid ablation across Asia via peer-to-peer clinical education and local institutional engagement.

Which physicians participated in Baird Medical's U.S. training for BDMD technology?

Participants included Dr. Jennifer Kuo, Dr. Todd Frieze, and Dr. Alberto Monreal in the U.S. program. According to the company, these specialists refined minimally invasive ablation procedures using Baird Medical's Microwave Ablation System.

What clinical focus did Baird Medical (BDMD) emphasize in its recent programs?

The programs emphasized standardized interventional thyroidology and non-surgical treatment of benign thyroid tumors. According to the company, the training targeted technique refinement and broader patient access to MWA therapies.

What is the investor relevance of Baird Medical's (BDMD) training initiatives?

The initiatives aim to accelerate clinical adoption and international market presence for MWA technology. According to the company, standardized training at leading institutions supports commercial rollout and broader clinical acceptance over time.